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OBJECTIVE: Tranexamic acid (TXA) and the hemostatic agent Floseals have already been used to minimize
bleeding during total knee arthroplasty (TKA).
METHODS: We conducted a prospective, randomized study of 90 patients with indications for TKA. Following
inclusion, the participants were randomly allocated in blocks to the following 3 groups: control, Floseals and
TXA. Bleeding parameters, including decreases in hemoglobin (Hb), drain output, number of blood transfusions
and complications, were assessed. ClinicalTrials.gov: NCT02152917.
RESULTS: The mean decrease in Hb was highest in the control group (4.81±1.09 g/dL), followed by the Floseals
(3.5±1.03 g/dL) and TXA (3.03±1.2 g/dL) groups. The Floseals and TXA groups did not differ, and both
performed better than the control group. The mean total drain output was 901.3±695.7 mL in the control
group, 546.5±543.5 mL in the TXA group and 331.2±278.7 mL in the Floseals group. Both TXA and Floseals
had significantly less output than the control group, and Floseals had significantly less output than TXA. The
number of blood transfusions was very small in all 3 groups.
CONCLUSION: The use of TXA or Floseals was associated with less blood loss than that of the control group
among patients undergoing primary TKA, as measured both directly (intraoperative bleeding+ drainage) and
on the basis of a decrease in Hb, without differences in the rate of complications. TXA and Floseals showed
similar decreases in Hb and total measured blood loss, but the drain output was smaller in the Floseals group.
KEYWORDS: Total Knee Arthroplasty; Bleeding Control; Tranexamic Acid; Hemostatic; Transfusion Rate.
’ INTRODUCTION
The number of knee arthroplasty (TKA) procedures per-
formed per year is expected to gradually increase as a function
of population aging and increases in life expectancy. According
to American estimates, the annual number of procedures
will increase to 3 million by 2030 (1,2). Although TKA is well
established as a treatment for knee arthritis, several issues
relating to the perioperative clinical control of patients still
remain, particularly regarding complications associated with
clinical comorbidities and surgery-induced bleeding.
Tranexamic acid (TXA) has been suggested as a therapeu-
tic option to minimize blood loss. Several studies have
reported excellent results with the intravenous administra-
tion of TXA during the perioperative period in terms of
bleeding reduction, decreases in hemoglobin (Hb) levels and
a decreased need for blood transfusions (1-6). However, the
association of TXAwith thrombotic events is a cause of much
concern, and consequently, most studies have excluded
patients with comorbidities that are likely to increase the
risk of thrombosis. Whiting et al. (7) assessed the use of TKA
in high-risk patients and did not observe an increase in
thromboembolic events. However, theirs was a retrospec-
tive study, and thus, it is not yet possible to assert whether
TXA is completely safe for this population of patients. Most
surgeons avoid using TXA when there is a higher percei-
ved risk of thrombotic events, such as in patients with a
history of venous thromboembolism or ischemic cardiovas-
cular events.
Another approach to minimize bleeding is based on the
use of topical hemostatic agents, such as Floseals (Baxter).
This compound is composed of human thrombin and bovine-
derived gelatin and is designed for topical use (8). Some
studies have reported significant benefits of using hemostatic
agents to control bleeding in several medical areas (9-12),
including orthopedic surgery (13-18), but its action has not yet
been well established in TKA.DOI: 10.6061/clinics/2019/e1186
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ORIGINAL ARTICLE
To the best of our knowledge, no studies have compared
TXA and Floseals. Therefore, it is not yet known whether
their effects on bleeding control are comparable and thus
whether Floseals may be used in place of TXA in cases of
contraindication. Therefore, we conducted a randomized,
prospective study comprising 3 groups (TXA, Floseals and
control) to first compare the efficacy of TXA and a hemostatic
agent for controlling perioperative bleeding in TKA, using
direct measurement (intraoperative bleeding + drain out-
put) and a decrease in the Hb concentration, and secondarily
to assess the respective rates of complications. Our hypoth-
eses were that both treatments would be more efficient than
the control treatment and that TXAwould be superior to the
topical hemostatic agent.
’ MATERIALS AND METHODS
The present prospective, randomized study was conducted
with an initial population of 90 patients with indications for
TKA. The study was approved by the institutional research
ethics committee, and all of the participants signed informed
consent forms. The protocol was registered at clinicaltrials.gov
under NCT02152917. The inclusion criteria are described in
Table 1, and these criteria were selected to avoid including
patients with high odds of bleeding or postoperative (PO)
complications.
Following inclusion, the participants were randomly allo-
cated in blocks to the following 3 groups: control, Floseals
and TXA.
All TKA procedures were performed in the standard
manner using pneumatic tourniquets and the medial para-
patellar and transquadricipital approach without patellar
eversion. An intramedullary guide was used for the femoral
cut, and an extramedullary guide was used for the tibial cut.
The posterior cruciate ligament was resected, and the patellar
cut was performed in all cases. Cement fixation was per-
formed on all patients, none of whom received any type
of periarticular infiltration. In all patients, the pneumatic
tourniquet was released after cementation. A compressive
dressing was applied to the open wound for 5 minutes after
the release of the tourniquet, and electrocautery was used as
needed before closure.
The anesthetist was the only member of the surgical staff
who had knowledge of the group the participants belonged
to before and during surgery and was responsible for the
administration of TXA. In the Floseals group, the surgeon
was informed and handled the product for application at the
time of pneumatic tourniquet release (when the surgeon was
informed of the group to which the patient was allocated).
The participants in the control group received no other treat-
ments than those usually administered during surgery.
Floseals was applied to the potential bleeding sites, parti-
cularly the posterior, superior, medial and lateral recesses,
before the pneumatic tourniquet was released and the
surgical approach was then tamponed with a compressive
dressing (Figure 1). After the tamponed period (five min-
utes), the product was again applied to the bleeding sites
with a bandage at those points for two minutes. A total of
10 mL of Floseals was used, and it was distributed into
2 syringes (5 mL in each).
TXA was administered at a dose of 10 mg/kg at least
20 minutes before inflating the pneumatic tourniquet, and
Table 1 - Inclusion criteria.
- age above 21 years;
- male or female gender;
- indication for TKA for any cause;
- ability to read and understand the informed consent form;
- no previous history of open surgery on the knee (arthroscopy was
accepted);
- absence of inflammatory arthritis (e.g., rheumatoid arthritis);
- absence of knee stiffness (defined as flexion less than 75 degrees or
flexion contracture over 15 degrees) before surgery;
- absence of the following clinical conditions: kidney failure with
creatinine clearance o40 mL/min, liver failure, severe heart failure,
severe respiratory failure, history of thromboembolic events,
coagulation disorders and previous stroke.
Figure 1 - Application of Floseals to the surgical wound.
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another 10 mg/kg was administered before tourniquet
release. In the present study, we chose the dose and simplest
administration route for TXA from those reported in the
literature as being able to reduce bleeding and the need for
transfusion (1).
The follow-up time had a minimum of 12 months, and all
the parameters assessed are described in Table 2.
All participants received standard mechanical and phar-
macological prophylaxis against thromboembolism with
40 mg of enoxaparin once daily for 30 days, as it is the stan-
dard protocol at our institution. In addition, they received
oxygen via a catheter for 24 hours after surgery because of its
beneficial effects on wound healing according to recent litera-
ture (19). The drain was removed on PO day 2, within 46 to
48 hours after the procedure, and exercises targeting range
of motion and walking were started the day after surgery.
Statistical analysis was performed using Pearson’s chi-
square test or Fisher’s test for categorical variables. Con-
tinuous variables were described by the mean and standard
deviation, and Shapiro-Wilk tests and histograms were used
to check the normality of the data. We used a one-way ana-
lysis of variance (ANOVA) test for normally distributed
variables and the Kruskal-Wallis test for non-normally distri-
buted variables, as well as a post hoc test with Bonferroni
correction. An a priori sample size estimation of 90 patients
per group was chosen on the basis of a power of 80% to show
a clinically significant difference of 500 ml of total bleeding
between the intervention groups and the control group (20).
We used the statistical software SPSS 22 (IBM Corp.,
NY, USA) and G*Power 3.1.9.3 (Erdfelder, Faul, Buchner,
Universität Düsseldorf, Düsseldorf, Germany 2009).
’ RESULTS
A total of 90 patients were included in the study, with 30
allocated to each group, and none of the participants were
lost to follow-up during the study period. The mean values
of the investigated variables are described in Table 3.
The mean decrease in Hb was largest in the control group
(4.81±1.09 g/dL), followed by the Floseals (3.5±1.03 g/dL)
and TXA (3.03±1.2 g/dL) groups (po0.001). The hemo-
static and TXA groups did not differ in this parameter
(p=0.286), and both treatments showed a lower performance
than the control treatment (po0.05).
The mean drain output was 901.3±695.7 mL in the control
group, 546.5±543.5 mL in the TXA group and 331.2±278.7
mL in the Floseals group (po0.001). The drain output was
significantly higher in the control group than in the TXA
(po0.05) and Floseals (po0.05) groups (po0.001) and was
higher in the TXA group than in the Floseals group (p=0.016).
The amount of directly aspirated blood was different
between the three groups (p=0.001). Both the TXA and
Floseals groups had less aspirated blood than the control
group (p=0.001 and 0.05, respectively). The pad weight did
not differ between the TXA and Floseals groups (p=0.46)
and was smaller in these groups than in the control group
(po0.05). The amount of infused serum did not differ among
the groups (p=0.53).
The total bleeding volume (aspirated blood+ pad weight
difference+ drain output on PO day 2) was different between
the three groups (po0.001). It was higher in the control group
than in the TXA (1328 ml vs. 799 ml, p=0.001) and Floseals
(1328 ml vs. 626 ml, po0.05) groups, and there was no
statistically significant difference between TXA and Floseals
(799 ml vs. 626 ml, po0.001).
The number of blood transfusions was very small, with
only 1 patient from the Floseals and TXA groups and 2
patients from the control group requiring transfusion. Com-
plications included 1 case of superficial infection and 1 case
of deep vein thrombosis (DVT) in the control group, 1 case
of deep infection treated by debridement and polyethy-
lene exchange in the TXA group and 1 case of DVT in the
Floseals group. All complications were detected within the
first 3 months after surgery.
The results concerning range of motion (ROM) of the knees
are described in Table 4. The ROM was higher in the Floseals
group than in the control group on all 3 of the PO days
(po0.05). The ROM was also better in the Floseals group
than in the TXA group on PO days 2 and 3 (po0.05), but it
did not differ on PO day 1 (p=0.13). Comparing the TXA and
control groups, the ROM was similar on PO day 1 (p=0.11)
and better in the TXA group on the 2 following days
(po0.05). The groups did not differ in terms of gains in ROM
during the first 3 days after surgery.
’ DISCUSSION
The results of the present study corroborate previous
reports in the literature regarding the reduction of bleeding
by TXA in TKA and confirm the efficacy of the hemostatic
Table 2 - Parameters for evaluation.
- Weight of 30 pads before and after surgery to assess the amount of
blood absorbed during the intraoperative period
- Difference between the amounts of serum infused to irrigate the
surgical field and the volume suctioned during the intraoperative
period (suctioned blood volume)
- Output of the 3.2-mm vacuum drain (Portovac) until its removal
(which occurred on postoperative day 2 as per protocol)
- Amount of fluids infused during surgery (colloid and crystalloid
solutions)
- Decrease in the Hb level from the preoperative measurement to PO
day 3
- Need for and number of blood transfusions, indicated when an Hb
o8 g/dl was combined with the presence of clinical complications
- Occurrence of any thrombotic events with clinical manifestations
within 90 days of surgery and clinical signs and symptoms of infection.
- Occurrence of any adverse events during the short-term follow-up
that were likely to be related to the investigated medications
- Knee ROM during the first 3 days after surgery








until PO 2 (mL)
Hb decrease on PO
day 3 (g/dL)
Total measured bleeding
(suctioned + pads + drain)
TXA 55.2* 197.5 1 546.5*= 3.03* 799*
Control 122.5*w 304.6 2 901.3*w 4.81*w 1328*w
Floseals 59.9w 235.5 2 331.2w= 3.50w 626w
* ,w,=: po0.05 in comparison with other values in the same column.
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agent Floseals (6,17,18,21-25). In the present study, the use of
Floseals was associated with a smaller decrease in Hb levels
than that in the control (3.50 g/dL vs. 4.81 g/dL), this decrease
was not significantly different from that with TXA (3.50 g/dL
vs. 3.03). There are already published reports of reductions in
bleeding with the use of hemostatic agents (26-29). However,
there is considerable disagreement in the literature, as there
are also several studies with satisfactory methodology that
have not detected this difference (16,30,31).
Similar to those in another study (18), the rate of compli-
cations in our investigation, including infections and venous
thromboembolism, was small and did not differ among the
groups. Patients with severe comorbidities and risk factors
for thromboembolic complications were excluded from the
present study, and therefore, we did not expect adverse
events to have a high occurrence. Although Whiting et al. (7)
did not find an association between the use of TXA and an
increased frequency of thromboembolic events among high-
risk patients, this medication is not commonly used in this
group of patients in our country, and there is still a tendency
worldwide to avoid using TXA in the presence of a higher
risk of thromboembolic events.
One interesting finding of our study was that the initial
ROM of the knee was higher among the patients who received
Floseals. This parameter is not frequently assessed in studies
investigating the use of hemostatic and fibrinolytic agents,
but we believe it is of paramount importance because the
effects of these blood-loss management approaches on the
patients’ rehabilitation should be taken into consideration.
In addition to causing eventual clinical complications, joint
bleeding after TKA can impair the ROM of the knee due to
the presence of joint effusion, which causes pain and impairs
mobility. Although in the present study all of the groups
attained an average ROM of 90 degrees or more by PO day 3,
the hemostatic group exhibited a higher ROM on all 3 days,
and this was the only group to attain more than 90 degrees
on PO day 2 and more than 100 degrees on PO day 3; these
differences were statistically significant compared with the
control and TXA groups.
To the best of our knowledge, our study is the first to
include a group treated with TXA in addition to the control
group and to compare TXA to treatment with a topical
hemostatic agent. The results corresponding to both inter-
vention groups (Floseals and TXA) were superior to those
from the control group and were not different in terms of
reduced bleeding and a reduction of the decrease in Hb, and
both interventions were accompanied by similarly low rates
of complications. Therefore, we conclude that Floseals is a
viable resource for reducing bleeding in primary TKA, with
effects that are comparable to the more well-known TXA
treatment. The only factor that remains to be established is
the cost-benefit ratio, which was not assessed in the present
study.
Topical TXA has recently been further studied. Recent
studies have reported results that were similar to the use of
intravenous TXA, with less potential for complications
(32,33). Future studies comparing topical TXA and hemo-
static agents can now be conducted, as both treatments were
found to be equivalent to intravenous TXA. We believe that
all of these agents should be part of the therapeutic arsenal to
minimize perioperative bleeding so that patients exhibiting
contraindications to one of the agents might benefit from the
others. In cases with no contraindications, the choice may be
combined use or use of the agent with the best cost-benefit
ratio for the healthcare service.
In addition, we consider investigating the possible benefits
of the combined use of TXA and hemostatic agents to be
relevant because they have different mechanisms of action
and their effects might thus be potentiated. The combi-
ned approach might be beneficial considering the recent
trend toward a reduction in the lengths of hospital stays.
Rehabilitation of patients subjected to TKA can be initiated
earlier, and the use of postoperative drains can occasionally
be avoided.
The present study has certain limitations. Although the
surgeon was blinded to the randomization and was unaware
if the patient received the initial application of TXA during
surgery, blinding was not possible in the case of the hemo-
static agent, as it is applied by the surgeon during the surgi-
cal procedure. This might have resulted in some bias because
the surgeon was aware of the cases in which the hemostatic
agent was used at the end of hemostasis. Additionally, we
could not reject the null hypothesis that the total bleeding
volume was the same between the TXA and Floseals. As our
post hoc analysis showed that a minimal sample size of 124
subjects per group would be required to achieve a power of
0.8, there is a possibility of a type II error regarding this
finding. Nevertheless, in our judgment, the observed diffe-
rence of 174 ml was clinically too small to justify the increase
in sample size. Based on the results of the present study,
future trials should be conducted with topical TXA to
compare both topical treatments only.
’ CONCLUSION
The use of TXA or Floseals was associated with less blood
loss than that of the control group among patients under-
going primary TKA, as measured both directly (intraope-
rative bleeding + drainage) and on the basis of a decrease
in Hb, without differences in the rate of complications.
Table 4 - Mean ROM of the knees assessed for the prospective randomized trial comparing Floseals and TXA for bleeding control
after TKA.
Group Control TXA Floseals
Mean SD Mean SD Mean SD
PO day 1 65.8* 20.1 73.5 19.2 80.5* 9.9
PO day 2 80.2*= 14.7 85.7w= 11.8 93.4*w 11.4
PO day 3 90.0*= 9.3 95.6w= 8.3 102.4*w 7.9
Difference between PO day 1 and 3 24.2 16.9 22.1 17.1 21.9 10.4
PO – postoperative.
* ,w,=: po0.05 in comparison with other values on the same line.
TXA – Tranexamic acid.
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TXA and Floseals showed similar decreases in Hb and total
measured blood loss, but the drain output was smaller in
the Floseals group. Both interventional treatments exhibited
comparable effects. The transfusion of blood components was
infrequent in all 3 groups. Future investigations targeting the
clinical importance of the differences found in the present
study are necessary, as well as research investigating the
effects of hemostatic and TXA in combination.
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